VPN Plus+ ExclusiveValentine's Day hazards infographic downloadJanuary 28, 2026Help clients keep love in the air on Valentine's Day! On a day filled with chocolates, roses, and other pet no-nos, this infographic reminds clients of the signs of chocolate toxicity and which other foods and decorations they need to keep out of reach. Feel free to post in your waiting room, on your socials, or use as an email blast to clients!
SPONSORED CONTENTHow can you help new pet owners keep their new dogs protected?See why new dog owners and their pets can benefit from simple triple protection in one monthly chew. + See the Difference
VPN Plus+ ExclusiveUnraveling pelvic limb dysfunction in a young canine patientJanuary 21, 2026This article features a puppy with an acute, progressive onset of pelvic limb dysfunction. The purpose of this article is to guide the reader through: 1)The process of determining the affected anatomic region 2) Generating a list of differential diagnoses 3) Determining the diagnostic plan 4) Formulating treatment options
A close look at monoclonal antibodies for managing canine OA painJanuary 15, 2026As veterinary care continues to shift toward preventive medicine and lifelong wellness, there is growing momentum around improving earlier detection and more consistent pain management. Among the emerging therapeutic options is a new class of biologics: monoclonal antibodies (mAbs).
Brain Teaser: Can you solve this puzzle?January 7, 2026Presentation: A five-month-old intact female Pomeranian with right forelimb lameness after jumping off a step.
USDA approves drug for canine allergic and atopic dermatitisJanuary 6, 2026Befrena (tirnovetmab), an anti–IL-31 monoclonal antibody injection for the treatment of canine allergic and atopic dermatitis, is intended for use in dogs of any age and is recommended at dosing intervals of six to eight weeks following treatment.
Providing therapeutic options to manage canine atopic dermatitisDecember 30, 2025Veterinarians need a solid understanding of the available therapeutic options to make appropriate recommendations for patients. Additionally, understanding our clients’ perspectives is key to devising successful management plans that fit their needs and desired outcomes.
VPN Plus+ ExclusiveNon-Surgical Treatment Options for Pyometra and Pregnancy TerminationDecember 26, 2025Bruce Christensen, DVM, MS, DACT, discusses reasons for considering medical options over surgical spay for cases of canine pyometra and pregnancy termination. Dr. Christensen will then explain the available medical treatment options including protocols, efficacy, and side effects. These include prostaglandins, dopamine agonists, steroids, and progesterone receptor blockers.
Canine parvo preventative gets full USDA approvalDecember 16, 2025The product, now approved as a therapeutic for canine parvovirus, marks the first USDA-approved treatment for the disease beyond supportive care and will be marketed under the name Trutect.
Managing IVDD: When to medicate, when to referDecember 16, 2025This article will review the current thinking on medical versus surgical management of IVDD, including what signs should trigger an urgent referral. With a practical grading system, recovery expectations, and client communication strategies, this guide is designed to give general practitioners confidence in handling one of the most stressful situations their clients may face.
VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
